Science

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies

Elizabeth McKenna/X

Mar 24, 2025, 13:36

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies

Elizabeth McKenna, Executive Director of Cancer Discovery at the American Association for Cancer Research, shared an article by Mansi Saxena, et al. on X:

“Now in Cancer Discovery:

PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform:

Phase I Study in Patients with Solid & Hematological Malignancies in the Adjuvant Setting – by Mansi Saxena, Tom Marron, Philip Friedlander, Alex rubinsteyn, Bhardwaj Lab, et al.”

PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematological malignancies in the adjuvant setting.

Authors: Mansi Saxena, et al.

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies

AACR alex rubinsteyn American Association for Cancer Research Bhardwaj Lab cancer Cancer Discovery Elizabeth McKenna fight against cancer Global fight against cancer hematological malignancies Mansi Saxena OncoDaily Oncology PGV001 Philip Friedlander Tom Marron

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More